Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 30;10(5):e165.
doi: 10.1192/bjo.2024.787.

Inflammatory biomarkers in depression: scoping review

Walter Paganin  1 , Sabrina Signorini  2
Affiliations

Inflammatory biomarkers in depression: scoping review

Walter Paganin et al. BJPsych Open. .

Abstract

Background: Inflammation is increasingly recognised as a fundamental component of the pathophysiology of major depressive disorder (MDD), with a variety of inflammatory biomarkers playing pivotal roles. These markers are closely linked to both the severity of symptoms and the responsiveness to treatments in MDD.

Aims: This scoping review aims to explore the scientific literature investigating the complex relationships between inflammatory biomarkers and depression, by identifying new studies and critical issues in current research.

Method: Following the PRISMA Extension for Scoping Reviews guidelines, we systematically searched databases including PubMed, Scopus, PsycINFO, Open Grey and Cochrane Library. Our search focused on articles published from 1 January 2020 to 1 May 2024. We included studies evaluating inflammatory biomarkers in adult patients with MDD, utilising observational and randomised controlled trial designs, and review studies.

Results: Our analysis examined 44 studies on the complex interplay between inflammation and its multiple effects on MDD. Significant associations between specific inflammatory biomarkers and depression severity were found, requiring cautious interpretation. We also highlight several methodological limitations in the current studies, which warrant caution in directly applying these findings to clinical practice. However, identified methodologies show potential for using these biomarkers as diagnostic tools or therapeutic targets, including anti-inflammatory interventions.

Conclusions: The findings emphasise the need for sophisticated, integrative research to understand inflammation's role in MDD. Future studies should identify specific biomarker panels for diagnosing depression and bridging peripheral biomarker measurements with central neuroinflammatory processes, leading to better diagnostic and treatment strategies.

Keywords: Depression; biomarkers; neuroinflammation; pro-inflammatory cytokines; review.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram of the study selection process.
See this image and copyright information in PMC

References

    1. Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2019 (GBD 2019) Results. IHME, University of Washington, 2019 (https://ghdx.healthdata.org/gbd-2019).
    1. Santomauro DF, Mantilla Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigott DM, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021; 398(10312): 1700–12. - PMC - PubMed
    1. Santosh Kore M, Prabhavalkar KS. Biomarkers for the diagnosis of depression: recent updates. Curr Psychiatry Res Rev 2023; 19(3): 214–34.
    1. Atala A, Allickson JG, editors. Translational Regenerative Medicine. Elsevier, 2015.
    1. Brody T. Biomarkers. In Clinical Trials (ed T Brody): 377–419. Academic Press, 2016.

Publication types

LinkOut - more resources